The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 103 results:
Author Title Type [ Year(Asc)]
Filters: Keyword is Antineoplastic Combined Chemotherapy Protocols  [Clear All Filters]
2019
Pentheroudakis, G., Mavroeidis L., Papadopoulou K., Koliou G-A., Bamia C., Chatzopoulos K., et al. (2019).  Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.. Clin Colorectal Cancer. 18(4), e370-e384.
Pavlidis, E. T., & Pavlidis T. E. (2019).  A Review of Primary Thyroid Lymphoma: Molecular Factors, Diagnosis and Management.. J Invest Surg. 32(2), 137-142.
2018
Pentheroudakis, G., Kotoula V., Koliou G-A., Karavasilis V., Samantas E., Aravantinos G., et al. (2018).  AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer.. Clin Colorectal Cancer. 17(4), e631-e637.
Kaiafa, G., Bobos M., Savopoulos C., Koutsokostas T., Kouskouras K., Kalogera-Fountzila A., et al. (2018).  Heart and lymphoma: An unusual case of secondary cardiac lymphoma manifested through presyncope and syncope episodes and atrial flutter.. Hellenic J Cardiol. 59(3), 182-185.
Katodritou, E., Kyrtsonis M-C., Delimpasi S., Kyriakou D., Symeonidis A., Spanoudakis E., et al. (2018).  Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.. Ann Hematol. 97(9), 1671-1682.
2017
Mainou, M., Madenidou A-V., Liakos A., Paschos P., Karagiannis T., Bekiari E., et al. (2017).  Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis.. Eur J Haematol. 98(6), 563-568.
Konstantinidis, I. T., Chouliaras K., Levine E. A., Lee B., & Votanopoulos K. I. (2017).  Frailty Correlates with Postoperative Mortality and Major Morbidity After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.. Ann Surg Oncol. 24(13), 3825-3830.
Ziogas, D. C., Kastritis E., Terpos E., Roussou M., Migkou M., Gavriatopoulou M., et al. (2017).  Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens.. Leuk Lymphoma. 58(8), 1832-1839.
Gavriatopoulou, M., Kastritis E., Kyrtsonis M-C., Vassilakopoulos T. P., Roussou M., Fotiou D., et al. (2017).  Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia.. Leuk Lymphoma. 58(6), 1506-1508.
2016
Dimopoulos, M. A., Roussou M., Gavriatopoulou M., Psimenou E., Eleutherakis-Papaiakovou E., Migkou M., et al. (2016).  Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.. Am J Hematol. 91(5), 499-502.
Stavridi, F., Kalogeras K. T., Pliarchopoulou K., Wirtz R. M., Alexopoulou Z., Zagouri F., et al. (2016).  Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study.. PLoS One. 11(10), e0164013.
Kotoula, V., Karavasilis V., Zagouri F., Kouvatseas G., Giannoulatou E., Gogas H., et al. (2016).  Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.. Breast Cancer Res Treat. 158(2), 307-21.
Matikas, A., Kentepozidis Ν., Ardavanis A., Vaslamatzis M., Polyzos A., Emmanouilides C., et al. (2016).  Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG).. Cancer Chemother Pharmacol. 78(2), 369-76.
Cohen, S. A., Wu C., Yu M., Gourgioti G., Wirtz R., Raptou G., et al. (2016).  Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.. Clin Colorectal Cancer. 15(2), 164-9.
Fotiou, D., Dimopoulos M. A., & Kastritis E. (2016).  Managing renal complications in multiple myeloma.. Expert Rev Hematol. 9(9), 839-50.
Meille, C., Barbolosi D., Ciccolini J., Freyer G., & Iliadis A. (2016).  Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy.. Clin Pharmacokinet. 55(8), 1015-25.
Hénin, E., Meille C., Barbolosi D., You B., Guitton J., Iliadis A., et al. (2016).  Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients.. Breast Cancer Res Treat. 156(2), 331-41.
Tragiannidis, A., Gombakis N., Papageorgiou M., Hatzipantelis E., Papageorgiou T., & Hatzistilianou M. (2016).  Treatment-related myelodysplastic syndrome (t-MDS)/acute myeloid leukemia (AML) in children with cancer: A single-center experience.. Int J Immunopathol Pharmacol. 29(4), 729-730.
2015
Wu, S-C., Li L. S., Kopp N., Montero J., Chapuy B., Yoda A., et al. (2015).  Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.. Cancer Cell. 28(1), 29-41.
Kastritis, E., Gavriatopoulou M., Kyrtsonis M-C., Roussou M., Hadjiharissi E., Symeonidis A., et al. (2015).  Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.. Blood. 126(11), 1392-4.
Carvajal-Hausdorf, D. E., Schalper K. A., Pusztai L., Psyrri A., Kalogeras K. T., Kotoula V., et al. (2015).  Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.. J Natl Cancer Inst. 107(8), 
Saridaki, Z., Lambrodimou G., Kachris S., Makrantonakis P., Boukovinas I., Polyzos A., et al. (2015).  Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma.. Am J Clin Oncol. 38(1), 17-22.
Pectasides, D., Karavasilis V., Papaxoinis G., Gourgioti G., Makatsoris T., Raptou G., et al. (2015).  Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or. BMC Cancer. 15, 384.
2014
Lakis, S., Kotoula V., Eleftheraki A. G., Batistatou A., Bobos M., Koletsa T., et al. (2014).  The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping.. Breast. 23(3), 234-43.
Apalla, Z., Lallas A., Tzellos T., Sidiropoulos T., Lefaki I., Trakatelli M., et al. (2014).  Applicability of dermoscopy for evaluation of patients' response to nonablative therapies for the treatment of superficial basal cell carcinoma.. Br J Dermatol. 170(4), 809-15.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.